TECFIDERA is covered as a first-line relapsing MS therapy (unrestricted access) for 87% of commercial patients as of March 2019.
*Coverage may vary, and there is no guarantee of coverage.
The Biogen Copay Program may lower medication cost to as low as $0 for eligible patients with commercial insurance.
Depending on income or, in some cases, if medication is obtained from an out-of-network provider, there may be an annual cap that limits the amount of assistance patients can receive over 1 year. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, the VA/DoD, or any other federal plans are not eligible to enroll. Patients may be eligible to enroll in the Biogen Copay Program for as long as it is offered and as long as they are treated with a Biogen relapsing MS medication.